Hims & Hers vs Ro
Two GLP-1 desks, one scoreboard. We put Hims & Hers and Ro head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.
The verdict
Ro takes this head-to-head.
Ro scores 87 to 85 on our six-factor Brief Score — A heavyweight platform with brand-name access and a polished experience — but it keeps compounded pricing off the record.
That doesn't make Hims & Hers a bad call — it's best for readers who want a familiar, app-driven consumer brand and nationwide access. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Hims & Hers | Ro | |
|---|---|---|
| Brief Score | 85/100 (B) | 87/100 (B+) |
| Semaglutide | $199/mo | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | All 50 states | Multi-state |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
| On the tracker | Risingprice rising | Stableprice stable |
Hims & Hers: App-first reach is nationwide, but compounded supply has drawn industry-wide scrutiny.
Ro: Brand-name access and insurance navigation, but compounded pricing stays off the record.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.